Figure 2.
Alt text: Forest plot graphs with panels A to D showing calculated incidence of breakthrough fungal infections on isavuconazole prophylaxis based on different studies, with each horizontal line representing a 95% confidence interval and each square marker representing a pooled effect size.

Pooled incidence of bIFI. A, Pooled incidence of proven or probable bIFI in patients receiving any type of ISA prophylaxis, according to the EORTC/MSG 2008 criteria. B, Pooled incidence of possible, probable, or proven bIFI in patient undergoing any type of ISA prophylaxis, according to the EORTC/MSG 2008 criteria. C, Pooled incidence of bIFI per author definition in patients using ISA as the only primary prophylaxis. D, Pooled incidence of bIFI per author definition in patients receiving any type of ISA prophylaxis. bIFI, breakthrough fungal infection; EORTC/MSG, European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group; ISA, isavuconazole.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close